dual agonist glp 1 PDB-101: Molecule of the Month: GLP-1 Receptor Agonists Tirzepatide, a dual GIP/GLP-1 receptor
Description
Participants Patients with type 2 diabetes
95% CI, -0.02 to 0.03
Despite the potential clinical benefits of GLP-1RA plus SGLT2i combination therapy in patients with T2DM, several factors may delay this combination to become a common practice soon, such as reimbursement and costs associated with polypharmacy
RELIEVES THE 4 WORST GLP-1 SIDE EFFECTS IN ONE FORMULA Constipation that lasts 46 days
Across large employers that cover the drugs for weight loss, many require participation in lifestyle or nutrition programs before coverage applies
